Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

Abstract:

:Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly improve the course of the illness. Positive psychotic symptoms remit in the majority of patients who are treated with adequate trials of antipsychotic medications, but most relapse within 1 year. Non-adherence is strongly related to the likelihood of recurrence of symptoms. Innovative programmes that integrate early intervention, psychosocial treatments and atypical antipsychotic pharmacotherapy show promise in improving outcomes. The available research supports the use of antipsychotic medications early in the first-episode of schizophrenia and for at least 1 year after remission of positive symptoms. Antidepressants, benzodiazepines and mood stabilisers have roles in the acute and maintenance phases of treatment for some patients. Atypical antipsychotics represent a great advance in the treatment of first-episode schizophrenia with strong evidence for greater tolerability with equal or better therapeutic efficacy. Future research will further define their roles in treatment and hopefully identify targets for prevention of first-episode schizophrenia.

journal_name

Drugs

journal_title

Drugs

authors

Bradford DW,Perkins DO,Lieberman JA

doi

10.2165/00003495-200363210-00001

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

2265-83

issue

21

eissn

0012-6667

issn

1179-1950

pii

63211

journal_volume

63

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Gatifloxacin: a review of its use in the management of bacterial infections.

    abstract:UNLABELLED:Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent. The drug has a broader spectrum of antibacterial activity than the older fluoroquinolones (e.g. ciprofloxacin) and shows good activity against many Gram-positive and Gram-negative pathogens, atypical organisms and some anaerobes. Notably, gati...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262010-00007

    authors: Perry CM,Ormrod D,Hurst M,Onrust SV

    更新日期:2002-01-01 00:00:00

  • Epidemiology and therapy of Chlamydia trachomatis infections.

    abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198427050-00005

    authors: Bowie WR

    更新日期:1984-05-01 00:00:00

  • Recent advances in the pharmacological management of pain.

    abstract::Pain is an unpleasant sensation that originates from ongoing or impending tissue damage. Management of different types of pain (acute, postoperative, inflammatory, neuropathic or cancer) is the most frequent issue encountered by clinicians and pharmacological therapy is the first line of approach for the treatment of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767150-00002

    authors: Guindon J,Walczak JS,Beaulieu P

    更新日期:2007-01-01 00:00:00

  • Brexpiprazole: First Global Approval.

    abstract::Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0462-2

    authors: Greig SL

    更新日期:2015-09-01 00:00:00

  • Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

    abstract::Chronic spontaneous urticaria (CSU) is characterized by the presence of wheals, angioedema, or both for at least 6 weeks. It may persist for a long time-up to 50% of the patients have been reported to be symptomatic 5 years after the onset. Some patients can suffer more than one episode of CSU during their lifetime. C...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-020-01387-9

    authors: Giménez-Arnau AM,Salman A

    更新日期:2020-11-01 00:00:00

  • Heparin Therapy: regimens and management.

    abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197713010-00005

    authors: Deykin D

    更新日期:1977-01-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Risk factors for the spread of antibiotic-resistant bacteria.

    abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855030-00001

    authors: Rao GG

    更新日期:1998-03-01 00:00:00

  • Optimum management of nausea and vomiting in cancer chemotherapy.

    abstract::Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198734010-00005

    authors: Triozzi PL,Laszlo J

    更新日期:1987-07-01 00:00:00

  • Management of cystitis in young women.

    abstract::The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197713020-00003

    authors: Bailey RR

    更新日期:1977-02-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197800151-00016

    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

    abstract::The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01101-4

    authors: Deeks ED

    更新日期:2019-04-01 00:00:00

  • Protective effects of calcium antagonists against ischaemia and reperfusion damage.

    abstract::The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199100421-00005

    authors: Ferrari R,Visioli O

    更新日期:1991-01-01 00:00:00

  • Diuretics. Clinical pharmacology and therapeutic use (Part II).

    abstract::25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529020-00003

    authors: Lant A

    更新日期:1985-02-01 00:00:00

  • Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

    abstract::Alfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345030-00008

    authors: Wilde MI,Fitton A,McTavish D

    更新日期:1993-03-01 00:00:00

  • Letermovir: First Global Approval.

    abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0860-8

    authors: Kim ES

    更新日期:2018-01-01 00:00:00

  • Gram-positive cocci infections in intensive care: guide to antibacterial selection.

    abstract::The incidence of multiresistance in Gram-positive cocci causing infections in critically ill patients admitted to the intensive care unit (ICU) has increased notably in recent years. Thus, therapeutic proposals have been modified according to the emergence of multiresistant cocci and adapted to epidemiological markers...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666060-00003

    authors: Alvarez-Lerma F,Grau S,Gracia-Arnillas MP

    更新日期:2006-01-01 00:00:00

  • Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.

    abstract::Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID g...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11633740-000000000-00000

    authors: Roth SH

    更新日期:2012-05-07 00:00:00

  • Depression, circadian rhythms and trimipramine.

    abstract::During depression, chronobiological disorders occur, such as disturbances in body temperature and early urinary excretion of a noradrenaline metabolite. Sleep patterns are disturbed in 90% of depressed patients; early REM sleep and shortened slow-wave sleep (stages 3 and 4), resulting in an increase in REM sleep, have...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198900381-00003

    authors: Rüther E

    更新日期:1989-01-01 00:00:00

  • Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

    abstract::Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141050-00008

    authors: Deget F,Brogden RN

    更新日期:1991-05-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • A comparison of roxatidine acetate and ranitidine in gastric ulcer healing.

    abstract::A randomised multicentre double-blind study was conducted to compare the efficacy and safety of roxatidine acetate 75 mg twice daily and ranitidine 150 mg twice daily in 295 patients with endoscopically confirmed gastric ulcers. Substantial reductions in ulcer diameters and healing rates of 85.6 and 88.2% for roxatidi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00021

    authors: Judmaier G

    更新日期:1988-01-01 00:00:00

  • Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

    abstract::Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855010-00005

    authors: Hebart H,Kanz L,Jahn G,Einsele H

    更新日期:1998-01-01 00:00:00

  • Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

    abstract::The current challenge facing clinicians is to develop pharmacotherapies that move beyond the treatment of symptoms towards a new agenda in cardiovascular therapeutics that includes interventions to actually prevent the development of end-stage coronary heart disease. The development of new strategies to alter the natu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700545-00003

    authors: Gibbons GH

    更新日期:1997-01-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Methylnaltrexone.

    abstract::Methylnaltrexone is a selective mu-opioid receptor antagonist that has restricted ability to cross the blood-brain barrier, thus enabling reversal of opioid-induced peripheral effects, such as constipation, without affecting the central effects, such as pain relief. Treatment with subcutaneous methylnaltrexone 0.15-0....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204520-000000000-00000

    authors: Garnock-Jones KP,McKeage K

    更新日期:2010-05-07 00:00:00

  • Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

    abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464230-00005

    authors: Keating GM,Plosker GL

    更新日期:2004-01-01 00:00:00

  • Danoprevir: First Global Approval.

    abstract::Ascletis has developed danoprevir (Ganovo®), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0960-0

    authors: Markham A,Keam SJ

    更新日期:2018-08-01 00:00:00

  • The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

    abstract::Tuberous sclerosis complex (TSC) is a genetic disorder arising from mutations in the TSC1 or TSC2 genes. The resulting over-activation of the mammalian target of rapamycin (mTOR) signalling pathway leaves patients with TSC susceptible to the growth of non-malignant tumours in multiple organs. Previously, surgery was t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0552-9

    authors: Curatolo P,Bjørnvold M,Dill PE,Ferreira JC,Feucht M,Hertzberg C,Jansen A,Jóźwiak S,Kingswood JC,Kotulska K,Macaya A,Moavero R,Nabbout R,Zonnenberg BA

    更新日期:2016-04-01 00:00:00

  • Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

    abstract::The disposition of many drugs in cystic fibrosis is abnormal. In general, changes in pharmacokinetics include: increased volume of distribution, decreased plasma concentration, and enhanced renal and sometimes non-renal elimination of drugs. Pathophysiology of the disease important for drug disposition includes: (a) h...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835050-00004

    authors: Prandota J

    更新日期:1988-05-01 00:00:00